Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle Sells 4,949 Shares

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kura Oncology Price Performance

Shares of KURA stock opened at $7.69 on Thursday. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17. The company has a market capitalization of $598.01 million, a P/E ratio of -3.26 and a beta of 0.81. The stock has a 50 day moving average of $9.06 and a two-hundred day moving average of $15.63. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period in the prior year, the firm earned ($0.50) earnings per share. As a group, equities analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Wall Street Analyst Weigh In

KURA has been the topic of several analyst reports. HC Wainwright increased their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Scotiabank cut their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $27.38.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter. Moody Aldrich Partners LLC lifted its position in shares of Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after buying an additional 42,712 shares during the period. JPMorgan Chase & Co. boosted its stake in Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after buying an additional 3,092 shares in the last quarter. AQR Capital Management LLC grew its position in Kura Oncology by 251.5% in the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after acquiring an additional 58,422 shares during the period. Finally, Quarry LP acquired a new position in Kura Oncology during the second quarter worth $196,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.